高危前列腺癌三种主要治疗模式的疗效与毒性比较
该回顾性研究比较了1996至2012年间2557例高危前列腺癌患者接受外照射放疗(EBRT)、低剂量率近距离放疗(LDR)或根治性前列腺切除术(RP)的疗效与毒性。结果显示LDR和EBRT的生化无复发生存(bRFS)优于RP,临床无复发生存(cRFS)三组相当,LDR和RP在前列腺癌特异性死亡率(PCSM)上优于EBRT,且LDR的毒性最低。
要点
- LDR和EBRT的5年及10年bRFS均优于RP(P=.0001)。
- 三组cRFS无显著差异(P=.121)。
- LDR和RP的PCSM优于EBRT(P=.0004),LDR的≥3级毒性最低。
核心结论
- 高危前列腺癌接受EBRT、LDR或RP治疗,LDR和EBRT的bRFS优于RP,cRFS三组等效,LDR和RP的PCSM优于EBRT,LDR毒性最低。
研究设计与样本
- 回顾性研究纳入1996至2012年2557例高危前列腺癌患者,734例接受EBRT(联合或不联合ADT),515例接受LDR(联合或不联合ADT),1308例接受RP(联合或不联合EBRT)。
主要发现
- 中位随访63.5个月,中位年龄65岁。
- 5年和10年bRFS:EBRT为74%和53%,LDR为74%和52%,RP为65%和47%(P=.0001)。
- 5年和10年cRFS:EBRT为85%和73%,LDR为90%和76%,RP为89%和75%(P=.121)。
- 5年和10年PCSM:EBRT为5.3%和11.2%,LDR为3.2%和3.6%,RP为2.8%和6.8%(P=.0004)。
- 10年≥3级泌尿生殖毒性累积发生率:EBRT为8.1%,LDR为7.2%,RP为16.4%(P<.0001);≥3级胃肠道毒性:EBRT为4.6%,LDR为1.1%,RP为1.0%(P<.0001)。
临床怎么用
- 对于高危前列腺癌,LDR和EBRT在生化控制上优于RP,LDR和RP在降低前列腺癌特异性死亡上优于EBRT,LDR总体毒性最低,可作为个体化决策参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed. Toxicity was assessed using the Common Terminology Criteria for Adverse Events, version 4.03. The log-rank test compared bRFS and cRFS among the modalities, and Cox regression identified factors associated with bRFS and cRFS. Gray's test compared differences in late toxicity and PSCM among the modalities. Competing risk regression identified factors associated with PCSM. RESULTS: The median follow-up time and age were 63.5 months and 65 years, respectively. The bRFS at 5 and 10 years, respectively, was 74% and 53% for EBRT, 74% and 52% for LDR, and 65% and 47% for RP (P=.0001). The cRFS at 5 and 10 years, respectively, was 85% and 73% for EBRT, 90% and 76% for LDR, and 89% and 75% for RP (P=.121). The PCSM at 5 and 10 years, respectively, was 5.3% and 11.2% for EBRT, 3.2% and 3.6% for LDR, and 2.8% and 6.8% for RP (P=.0004). The 10-year cumulative incidence of ≥grade 3 genitourinary toxicity was 8.1% for EBRT, 7.2% for LDR, and 16.4% for RP (P<.0001). The 10-year cumulative incidence of ≥grade 3 gastrointestinal toxicity was 4.6% for EBRT, 1.1% for LDR, and 1.0% for RP (P<.0001). CONCLUSION: HRCaP treated with EBRT, LDR, or RP yields efficacy showing better bRFS for LDR and EBRT relative to RP, equivalence for cRFS, and a PCSM advantage of LDR and RP over EBRT. The toxicity is lowest for LDR.
引用
- Ciezki JP, Weller M, Reddy CA, et al. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28333019. doi:10.1016/j.ijrobp.2016.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。